Pfizer and Bristol stop a global trial of blood thinner apixaban

11/18/2010 | Bloomberg

Bristol-Myers Squibb and Pfizer have suspended an international, 10,800-participant study of apixaban after deciding that an increase in bleeding caused by the blood thinner outweighs clinical benefits for patients with acute coronary syndrome. "We knew there would be an increase in bleeding," a Bristol-Myers official said. "The question was whether we could achieve enough incremental efficacy to offset the incremental bleeding."

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA